Top-Rated StocksTop-RatedNASDAQ:CNTA Centessa Pharmaceuticals (CNTA) Stock Price, News & Analysis $16.79 +0.23 (+1.39%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$16.78 0.00 (-0.03%) As of 08/29/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Centessa Pharmaceuticals Stock (NASDAQ:CNTA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CNTA alerts:Sign Up Key Stats Today's Range$16.36▼$16.8850-Day Range$13.00▼$18.0552-Week Range$9.60▼$19.09Volume632,847 shsAverage Volume1.03 million shsMarket Capitalization$2.25 billionP/E RatioN/ADividend YieldN/APrice Target$31.50Consensus RatingBuy Company Overview Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom. Read More Centessa Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreCNTA MarketRank™: Centessa Pharmaceuticals scored higher than 52% of companies evaluated by MarketBeat, and ranked 530th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCentessa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCentessa Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Centessa Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Centessa Pharmaceuticals are expected to grow in the coming year, from ($1.60) to ($1.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Centessa Pharmaceuticals is -9.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Centessa Pharmaceuticals is -9.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCentessa Pharmaceuticals has a P/B Ratio of 5.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Centessa Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.10% of the float of Centessa Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCentessa Pharmaceuticals has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Centessa Pharmaceuticals has recently increased by 18.80%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCentessa Pharmaceuticals does not currently pay a dividend.Dividend GrowthCentessa Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.10% of the float of Centessa Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCentessa Pharmaceuticals has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Centessa Pharmaceuticals has recently increased by 18.80%, indicating that investor sentiment is decreasing significantly. News and Social Media3.5 / 5News Sentiment1.36 News SentimentCentessa Pharmaceuticals has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.11 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Centessa Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest4 people have searched for CNTA on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Centessa Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,472,814.00 in company stock.Percentage Held by InsidersOnly 7.09% of the stock of Centessa Pharmaceuticals is held by insiders.Percentage Held by Institutions82.01% of the stock of Centessa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Centessa Pharmaceuticals' insider trading history. Receive CNTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Centessa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNTA Stock News HeadlinesCentessa Pharmaceuticals (NASDAQ:CNTA) Research Coverage Started at Oppenheimer57 minutes ago | americanbankingnews.comCentessa rated Outperform at Oppenheimer on ORX750 potentialAugust 29 at 5:45 PM | seekingalpha.comNew Banking Law #1582 Could Unlock $21 Trillion for AmericansDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. If you do… | Brownstone Research (Ad)Reviewing Centessa Pharmaceuticals (NASDAQ:CNTA) and Prelude Therapeutics (NASDAQ:PRLD)August 22, 2025 | americanbankingnews.comPiper Sandler Remains a Buy on Centessa Pharmaceuticals (CNTA)August 19, 2025 | theglobeandmail.comCentessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025August 12, 2025 | finanznachrichten.deCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025August 12, 2025 | globenewswire.comTruist Initiates Buy on Centessa Pharmaceuticals (CNTA) with $30 PT, Cites Orexin Drug PotentialAugust 1, 2025 | msn.comSee More Headlines CNTA Stock Analysis - Frequently Asked Questions How have CNTA shares performed this year? Centessa Pharmaceuticals' stock was trading at $16.75 at the start of the year. Since then, CNTA stock has increased by 0.2% and is now trading at $16.79. How were Centessa Pharmaceuticals' earnings last quarter? Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) released its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.03. When did Centessa Pharmaceuticals IPO? Centessa Pharmaceuticals (CNTA) raised $285 million in an initial public offering (IPO) on Friday, May 28th 2021. The company issued 15,000,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Jefferies and Evercore ISI were co-managers. Who are Centessa Pharmaceuticals' major shareholders? Top institutional shareholders of Centessa Pharmaceuticals include Adage Capital Partners GP L.L.C. (6.27%), First Light Asset Management LLC (3.21%), Commodore Capital LP (2.47%) and Franklin Resources Inc. (1.90%). Insiders that own company stock include Antoine Yver, Arjun Goyal, David M Chao, Saurabh Saha, Mario Alberto Accardi, Thomas Templeman, Gregory M Weinhoff, Tia L Bush, Iqbal J Hussain, Harris Rotman and Karen M Anderson. View institutional ownership trends. How do I buy shares of Centessa Pharmaceuticals? Shares of CNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Centessa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Centessa Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and Southern First Bancshares (SFST). Company Calendar Last Earnings8/12/2025Today8/31/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CNTA CIK1847903 Webwww.centessa.com Phone44-73-9178-9784FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Price Target for Centessa Pharmaceuticals$31.50 High Price Target$40.00 Low Price Target$19.00 Potential Upside/Downside+87.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$235.76 million Net MarginsN/A Pretax Margin-1,510.27% Return on Equity-40.39% Return on Assets-29.87% Debt Debt-to-Equity Ratio0.32 Current Ratio10.11 Quick Ratio10.12 Sales & Book Value Annual Sales$6.85 million Price / Sales328.23 Cash FlowN/A Price / Cash FlowN/A Book Value$3.05 per share Price / Book5.50Miscellaneous Outstanding Shares133,910,000Free Float124,419,000Market Cap$2.25 billion OptionableOptionable Beta1.47 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:CNTA) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Centessa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.